VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

HLA Neoantigen Vaccine

Vaccine Information

Vaccine Name: HLA Neoantigen Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Type: Subunit vaccine
Status: Clinical trial
Host Species for Licensed Use: None
Antigen: autologous human leukocyte antigen (HLA) (Ott et al., 2017)
Immunization Route: Other
Description: Effective anti-tumour immunity in humans has been associated with the presence of T cells directed at cancer neoantigens, a class of HLA-bound peptides that arise from tumour-specific mutations. Vaccination with neoantigens can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. The vaccine targets up to 20 predicted personal tumour neoantigens. The vaccine induced CD4+ and CD8+ T cells responses. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour. (Ott et al., 2017)

Host Response

References

Ott et al., 2017: Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662); 217-221. [PubMed: 28678778].